Qianjiang Yongan Pharmaceutical Co., Ltd.

SZSE:002365.SZ

9.87 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

202320222021202020192018201720162015201420132012201120102009200820072006
Revenue 972.891,462.4481,565.4091,172.8541,370.4431,005.408932.772549.4555.894658.417522.718470.698417.015319.729310.299447.488314.988156.704
Cost of Revenue 721.213980.7891,206.87816.5051,051.724655.372592.465408.445457.315556.786437.77342.641314.437239.386207.579284.424209.967101.32
Gross Profit 251.677481.658358.539356.348318.719350.036340.306140.95498.579101.63284.948128.056102.57880.343102.72163.064105.02155.384
Gross Profit Ratio 0.2590.3290.2290.3040.2330.3480.3650.2570.1770.1540.1630.2720.2460.2510.3310.3640.3330.353
Reseach & Development Expenses 41.50140.44953.04446.66354.41723.98246.4740.9851.8562.0221.4120.404000.370.4220.2170
General & Administrative Expenses 85.77688.47527.07528.39722.29911.41115.5919.4088.4858.4766.9056.06415.00820.4634.1375.4434.4525.133
Selling & Marketing Expenses 38.761125.22678.76599.88881.50865.46854.8344.72746.32630.33926.08523.91918.05518.04213.86817.57817.4648.688
SG&A 174.965213.702105.839128.284103.80776.87970.42154.13454.8138.81532.9929.98333.06338.50518.00423.02121.91613.822
Other Expenses 28.40366.18569.69243.40843.98-0.0074.99811.0697.5535.95.282-1.1653.0114.8052.441.0811.148-0.095
Operating Expenses 244.869320.336228.574218.355202.204161.569160.16799.69397.29873.30167.86351.26234.05740.75529.06139.05329.72515.232
Operating Income 5.648152.403131.668133.973117.623212.293151.82262.94513.39632.73422.42389.82177.98446.81772.601119.74871.08438.542
Operating Income Ratio 0.0060.1040.0840.1140.0860.2110.1630.1150.0240.050.0430.1910.1870.1460.2340.2680.2260.246
Total Other Income Expenses Net 0.4030.658-1.818-3.395-1.271-0.2325.0310.767.4664.4535.25712.62914.89912.5291.3821.0810.784-0.095
Income Before Tax 6.052153.061129.851130.578116.352212.061156.85373.32820.86237.18727.67988.65680.99551.62275.041120.82971.86838.447
Income Before Tax Ratio 0.0060.1050.0830.1110.0850.2110.1680.1330.0380.0560.0530.1880.1940.1610.2420.270.2280.245
Income Tax Expense 34.46620.34110.80511.9199.44333.15823.89711.3393.6795.4654.67313.311.2275.5159.98918.2452.9180.985
Net Income -12.313140.349111.416105.5689.932178.584133.15162.29717.61331.72223.00775.35669.76846.10765.053102.58468.94937.462
Net Income Ratio -0.0130.0960.0710.090.0660.1780.1430.1130.0320.0480.0440.160.1670.1440.210.2290.2190.239
EPS -0.0420.480.380.370.310.620.460.220.060.110.080.270.250.170.310.490.370.23
EPS Diluted -0.0420.480.380.370.310.620.460.220.060.110.080.270.250.170.310.490.370.23
EBITDA 139.203293.381240.753242.594226.071291.868241.66112.0466.38783.98158.126101.50897.44265.02385.706127.54181.79540.775
EBITDA Ratio 0.1430.2180.1690.2260.1810.2930.280.2080.1440.1430.1110.2170.2090.2040.280.2850.2630.26